Bioalliance PharmaAct Nom. Cat-P News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.11.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2012 (Businesswire)
18.10.12	BioAlliance Pharma: New agreement signed for the distribution of Loramyc® in Iran with Shafayab Gostar (Businesswire)
05.10.12	BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at September 30, 2012 (Businesswire)
01.10.12	BioAlliance Pharma SA: Presentation of Phase I clinical results with AMEP® biotherapy in the treatment of metastatic melanoma (Businesswire)
24.09.12	BioAlliance Pharma announces the execution of its licensing agreement with Vestiq Pharmaceuticals for Oravig® in the US (Businesswire)
13.09.12	BioAlliance Pharma : Key milestones and consolidated accounts for the first semester of 2012 (Businesswire)
06.09.12	BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at August 31, 2012 (Businesswire)
06.08.12	BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at July 31, 2012 (Businesswire)
26.07.12	BioAlliance Pharma announces the grant of US patent covering Sitavig® (Businesswire)
19.07.12	BioAlliance Pharma announces a license agreement on Oravig® In the United States with Vestiq Pharmaceuticals (Businesswire)
19.07.12	BioAlliance Pharma announces a license agreement on Oravig® In the United States with Vestiq Pharmaceuticals (Businesswire)
12.07.12	BioAlliance Pharma extends and strengthens the protection of AMEP® with the grant of two patents in the US (Businesswire)
04.07.12	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at June 30, 2012 (Businesswire)
02.07.12	BioAlliance Pharma: Progress in the development of Loramyc® in Japan towards its registration by the partner Sosei (Businesswire)
18.06.12	BioAlliance Pharma Reinforces Its Development Team with the Appointment of Louis Kayitalire, MD, as Head of Research and Development (Businesswire)
13.06.12	BioAlliance Pharma and Teva Announce First License Agreement for Sitavig® for Israel (Businesswire)
04.06.12	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at May 31, 2012 (Businesswire)
31.05.12	BioAlliance Pharma: Combined Shareholders Meeting (Businesswire)
29.05.12	BioAlliance Pharma SA : Receivability of Sitavig® US Registration Dossier (NDA) for the Treatment of Recurrent Orofacial Herpes Validated by the FDA (Businesswire)
14.05.12	BioAlliance Pharma SA: Initiation of ReLive, phase III clinical trial with Livatag® In primary liver cancer (Businesswire)
10.05.12	BioAlliance Pharma: Disclosure of total number of voting rights and number of shares in the capital at April 30, 2012 (Businesswire)
26.04.12	BioAlliance Pharma Announces Two New Key Steps in the Development of Its AMEP® Biotherapy (Businesswire)
25.04.12	BioAlliance Pharma :Publication of the 2011 Registration Document (Businesswire)
25.04.12	BioAlliance Pharma: Combined Ordinary and Extraordinary General Meeting on May 31, 2012 (Businesswire)
17.04.12	BioAlliance Pharma: Full-Year Financial Results for 2011 (Businesswire)
17.04.12	BioAlliance Pharma Announces: New Achievements in Clonidine Lauriad™ Clinical Development, Second Product of Its Orphan Oncology Portfolio (Businesswire)
10.04.12	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2012 (Businesswire)
20.03.12	BioAlliance Pharma: Success of the first BioAlliance Pharma’s symposium « Oncology: key issues for the future » (Businesswire)
07.03.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at February 29, 2012 (Businesswire)
09.02.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at January 31, 2012 (Businesswire)
01.02.12	To Gain a Better Understanding of the Company, Its Product Portfolio and Its Management Team, BioAlliance Pharma Organizes a Symposium "Oncology: Key Issues for the Future" (Businesswire)
26.01.12	2011 Achievements and 2012 Prospects BioAlliance Pharma Confirms the Dynamics of Its Core Business (Businesswire)
23.01.12	BioAlliance Pharma Announces Two Key Steps with Its AMEP™ Biotherapy for Metastatic Melanoma (Businesswire)
06.01.12	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2011 (Businesswire)
04.01.12	BioAlliance Pharma: New Achievements in the Collaboration with Its Strategic European Partner, Therabel (Businesswire)
08.12.11	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2011 (Businesswire)
08.12.11	Hasbro Announces Quarterly Cash Dividend on Common Shares (Businesswire)
18.11.11	BioAlliance Pharma Ranked as France's Fastest Growing Company in the 2011 « Deloitte Technology Fast 50 » (Businesswire)
14.11.11	BioAlliance Pharma Reports Its Consolidated Turnover for Q3 (Businesswire)
09.11.11	Jack in the Box® Holiday Elves Raise Funds for Big Brothers Big Sisters (Businesswire)
09.11.11	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2011 (Businesswire)
05.09.11	BioAlliance Pharma: Presentation of Livatag® survival results at the international liver cancer congress in Hong Kong (Businesswire)
11.05.11	BioAlliance Pharma expands its Loramyc® franchise in Japan with Sosei in a deal valued up to 18.5M$ (Businesswire)
03.03.11	BioAlliance Pharma Receives €2 Million in Funding for Peptide Applications of the Patented LauriadTM Mucoadhesive Technology (Businesswire)
29.09.10	BioAlliance Pharma staff to participate in the Odyssea breast cancer charity fun run (Businesswire)
06.08.10	BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at July 30, 2010 (Businesswire)
16.04.10	BioAlliance Pharma Gains US FDA Approval for Oravig® (Loramyc® in EU) (Businesswire)
03.03.10	CORRECTING AND REPLACING:BioAlliance Pharma SA: Full-year accounts for 2009 (Businesswire)
09.02.10	BioAlliance Pharma Announces Its Consolidated Turnover for 2009 a Doubling in Recurring Revenues (Businesswire)
19.11.09	BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50™ (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Bioalliance PharmaAct Nom. Cat-P

Aktien Top/Flop

Meistgelesene Nachrichten